추가 설명:
Supplied as 0.2 mg/1 mL and 0.4 mg/2 mL presentations, this glycopyrrolate injection protects against peripheral muscarinic effects, such as bradycardia, caused by anticholinesterase agents like neostigmine when reversing neuromuscular blockade from non-depolarizing muscle relaxants. Its limited penetration of the blood-brain barrier keeps central nervous system effects minimal while reliably preventing peripheral muscarinic-like reactions.
평가 & 댓글 남기기